CTOs on the Move

Acadia Pharmaceuticals

www.acadia-pharm.com

 
Our Acadia family of care-ageous warriors aspire to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson`s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome. And in early-stage clinical research, we are exploring novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. Important Notice ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.acadia-pharm.com
  • 3611 Valley Centre Drive Suite 300
    San Diego, CA USA 92130
  • Phone: 858.558.2871

Executives

Name Title Contact Details
Nick Condos
Head of Information Security/Sr. Director Information Security Profile
Jerry Cipriani
Director, IT Data Services Profile
Nick C
Head of Information Security/Sr. Director Information Security Profile
Mark Schneyer
Executive Vice President and Chief Financial Officer Profile
Kim Alexander
Senior Director of Information Technology Profile

Similar Companies

VisionShare Inc

VisionShare Inc is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centro Latino de Chelsea

Centro Latino de Chelsea is a Chelsea, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Auburn Nursing Home

Auburn Nursing Home was founded in 1963 by Frank L. DeFurio, M.D. and Charles B. Richards, M.D. in response to a community need for long term care beds. Auburn Nursing Home opened it doors to the Community on December 1, 1964. Auburn Nursing Home still

Tru-Tain Inc

Tru-Tain Inc is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avexis Inc

AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.